XTL Biopharmaceuticals Ltd. (TLV:XTLB)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
4.900
-0.100 (-2.00%)
Aug 14, 2025, 5:24 PM IDT

XTL Biopharmaceuticals Company Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel.

Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome.

The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.

The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.

XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

XTL Biopharmaceuticals Ltd.
CountryIsrael
Founded1993
IndustryBiotechnology
SectorHealthcare
Employees10
CEONoam Band

Contact Details

Address:
26 Ben-Gurion St.
Ramat Gan, 5112001
Israel
Phone972 3 611 6600
Websitextlbio.com

Stock Details

Ticker SymbolXTLB
ExchangeTel Aviv Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberIL0010854979
SIC Code2836

Key Executives

NamePosition
Noam BandChief Executive Officer
Itay Weinstein CPAChief Financial Officer